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Background. Proteinases play a key role in emphysema. Bauhinia bauhinioides cruzipain inhibitor (BbCI) is a serine-cysteine
proteinase inhibitor. We evaluated BbCI treatment in elastase-induced pulmonary alterations. Methods. C57BL/6 mice received
intratracheal elastase (ELA group) or saline (SAL group). One group of mice was treated with BbCI (days 1, 15, and 21 after elastase
instillation, ELABC group). Controls received saline and BbCI (SALBC group). After 28 days, we evaluated respiratory mechanics,
exhaled nitric oxide, and bronchoalveolar lavage fluid. In lung tissue we measured airspace enlargement, quantified neutrophils,
TNF𝛼-, MMP-9-, MMP-12-, TIMP-1-, iNOS-, and eNOS-positive cells, 8-iso-PGF2𝛼, collagen, and elastic fibers in alveolar septa
and airways. MUC-5-positive cells were quantified only in airways. Results. BbCI reduced elastase-induced changes in pulmonary
mechanics, airspace enlargement and elastase-induced increases in total cells, and neutrophils in BALF. BbCI reducedmacrophages
and neutrophils positive cells in alveolar septa and neutrophils and TNF𝛼-positive cells in airways. BbCI attenuated elastic and
collagen fibers, MMP-9- and MMP-12-positive cells, and isoprostane and iNOS-positive cells in alveolar septa and airways. BbCI
reduced MUC5ac-positive cells in airways. Conclusions. BbCI improved lung mechanics and reduced lung inflammation and
airspace enlargement and increased oxidative stress levels induced by elastase. BbCI may have therapeutic potential in chronic
obstructive pulmonary disease.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of chronic respiratory morbidity and mortality and is
the fifth leading cause of death worldwide [1]. A proteinase-
antiproteinase imbalance is themost widely accepted hypoth-
esis to explain lung tissue destruction. In this context,
elastase secreted by neutrophils and macrophages may play
an important role in lung tissue destruction [2, 3].
Current COPD management involves patients reducing
their exposure to cigarette smoke, using inhaled bronchodila-
tors and corticosteroid, and receiving prompt treatment of
acute exacerbations [4]. However, we currently lack treat-
ments that reduce the progression or adequately suppress
the inflammation present in the small airways and lung
parenchyma of COPD patients. To better understand the
pathogenesis of emphysema, the elastase-induced model was
developed 50 years ago. It is a simple and widely usedmethod
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to induce emphysema in animals. This model has also been
used to test potential new therapeutic agents for COPD [5].
Proteinase inhibitors have been considered potential
treatments that could be used to modify the course of COPD.
In addition to degrading extracellular matrix proteins,
proteinases have important signaling functions in cell death,
cell proliferation, DNA replication, inflammatory response,
and tissue remodeling [6]. Thus, by inhibiting proteolytic
enzymes implicated in COPD pathogenesis, proteinase
inhibitors could reduce the progression of disease [7]. Some
proteinase inhibitors are also found in plants. Their role in
preventing excessive proteolysis during tissue inflammation
has been recently investigated [8, 9].
Bauhinia is a plant genus from subfamily Caesalpinioid-
eae, which comprisesmore than 600 species found in tropical
and subtropical forests.Many proteinase inhibitors have been
isolated from this genus, particularly from Bauhinia bauhin-
ioides. Bauhinia bauhinioides cruzipain inhibitor (BbCI) is
an 18 kDa Kunitz-type proteinase inhibitor isolated from
Bauhinia bauhinioides seeds [9]. BbCI inhibits the activity of
different serine proteinases, such as human neutrophil elas-
tase, porcine pancreatic elastase, and cathepsin G. BbCI also
inhibits the activity of cysteine proteinases, such as cathepsin
L, cruzipain, and cruzain [10]. The goal of this study was to
test the hypothesis that Bauhinia bauhinioides cruzipain
inhibitor (BbCI) limits elastase-induced alterations in pul-
monary mechanics, emphysema development, lung inflam-
mation, extracellularmatrix remodeling, and oxidative stress.
2. Materials and Methods
2.1. Animals and Study Design. Male C57Bl/6 mice (20–25 g)
were maintained in an animal facility with a 12-hour light-
dark cycle and fed with water and chow ad libitum. Animals
received human care in compliance with the “Guide for
Care and Use of Laboratory Animals” (National Institutes
of Health, publication 86-23, revised 1985). Protocols were
approved by the Ethical Committee of the University of Sa˜o
Paulo. Animals were divided into four groups of 8 animals
each: (a) animals that received a tracheal instillation and
intraperitoneal injection of vehicle (SAL, 𝑛 = 8); (b) animals
that received a tracheal instillation of elastase and intraperi-
toneal injection of vehicle (ELA, 𝑛 = 8); (c) animals that
received a tracheal instillation of saline and intraperitoneal
injection of BbCI (SALBC, 𝑛 = 8); (d) animals that received
a tracheal instillation of elastase and intraperitoneal injection
of BbCI (ELABC, 𝑛 = 8).
2.2. Elastase-Induced Emphysema Mouse Model. Six-week-
old C57Bl/6 mice were anesthetized with an intramuscular
injection of ketamine (40mg/kg) and xylazine (5mg/kg).
The trachea was exposed, and each animal received porcine
pancreatic elastase (0.667UI diluted in 50 𝜇L of sterile saline;
elastase type I/E-1250, Sigma-Aldrich, Saint Louis, USA)
directly into trachea. After instillation, we performed a chest
massage to spread the elastase in the lung. Control animals
received 50 𝜇L of sterile saline using the same method.
2.3. Inhibitor Expression and Purification. Overexpression of
the rBbCI in E. coli BL21 (DE3) cells and its purification were
carried out according to Ulian Arau´jo et al. [11]. Briefly, cells
containing the target gene cloned into the expression vector
pET28a (Novagen) were grown in Luria-Bertani medium
supplemented with 30 𝜇g/mL kanamycin (Invitrogen) at
37∘C to an optical density OD600 nm of 0.4, followed by
induction of the fusion-protein expression with isopropyl𝛽-
D-thiogalactopyranoside (Invitrogen). IPTG was added at a
final concentration of 1M and the culture was grown for
additional 3 hours and centrifuged (4000×g, 20min, 4∘C)
(Hitachi Himac CR21-GIII). The pellets were resuspended in
10mL of 0.05M Tris/HCl, pH 8.0 buffer, and 0.15M NaCl.
Bacterial cells disruption by sonication (Unique, Campinas,
Brazil) were lysed in 0.5% Triton X-114 (Sigma-Aldrich) (ten
cycles of ultrasound, 30 s, 30W) and centrifuged (4000×g,
20min, 4∘C). LPS was removed by addition of chloroform
(3 : 1, v/v) at 4∘C after centrifugation.The protein was further
purified by Ni–NTA affinity chromatography and eluted with
an imidazole gradient (100–250M) in the same sonication
buffer. The imidazole was removed by being dialyzed against
0.05M Tris/HCl, pH 8.0, and 0.15MNaCl buffer.TheHis-tag
was removed by digestion with 0.5U thrombin (GE Health-
care) per milligram of fusion protein for 4 h at 18∘C.The final
step of purification involved molecular exclusion chroma-
tography on a Superdex 75 HR 10/30 column (AKTA Purifier,
GE Healthcare) in 0.05M Tris/HCl, pH 8.0, and 0.15M NaCl
to separate the rBbCI protein from His-tag; the homogeneity
of the preparation was analyzed by SDS-PAGE and on 𝜇-
Bondapak C18 reverse phase column (Figure 1).
2.4. Treatment with BbCI. Two hours after the elastase
instillation, animals received the first dose of recombinant the
Bauhinia bauhinioides cruzipain inhibitor. On day 15 animals
received the second dose and on day 21 they received the
third dose. Each animal received 2mg/kg of BbCI diluted in
50mL of vehicle (saline) for each dose. In totality each animal
received 6mg/kg of BbCI.This dose was used in other studies
evaluating BbCI treatment [12]. Because the effect of BbCI is
dose-dependent, the animals received three doses (Figure 2).
2.5. Respiratory Mechanics Evaluation. Twenty-eight days
after the elastase or saline instillation, mice were anesthetized
with pentobarbital sodium (50mg/kg, ip) and tracheo-
stomized. Lung mechanics were measured using a computer-
controlled small animal ventilator (FlexiVent, Scireq, Mon-
treal, Canada). Animals were ventilated at 60 breaths/min
with a tidal volume of 20mL⋅kg−1. Oscillatory lung mechan-
ics were performed by producing flow oscillations at different
prime frequencies (from 0.25 to 19.625Hz). Pressure and
flow data were obtained. Airway impedance was calculated at
each frequency [13]. Airway resistance (Raw), tissue elastance
(Htis), tissue damping (Gtis), dynamic resistance (Rrs), and
dynamic elastance (Ers) parameters were obtained by using a
constant phasemodel that can separately analyze airways and
tissue. After these procedures, mice were killed by exsan-
guination.
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Figure 1: rBbCI purification from cells lysate. (a) Molecular exclu-
sion chromatography on a Superdex G-75 10/30 column equili-
brated with 50M Tris-HCl buffer containing 150M NaCl, pH 8.0.
(b) Reverse phase chromatograph, HPLC system 𝜇-BondapakC18.
SDS-PAGE (15%) from reverse phase chromatography on C18.
(M) Molecular mass standards; (1) rBbCI (30𝜇g) treated with 𝛽-
mercaptoethanol.
2.6. Bronchoalveolar Lavage. ABALwas performed by inject-
ing 0.5mL of sterile saline into the lungs through the tracheal
cannula and withdrawing the fluid into a tube on ice. The
recovered volume was approximately 90% of the volume
injected. This procedure was repeated three times. The
recovered fluidwas centrifuged at 800×g for 5min at 5∘C.The
cell pellet was resuspended in 1.0mLof physiological saline. A
total cell analysis was performed using a Neubauer hemocy-
tometer chamber and optical microscope with a 1000x mag-
nification. Cell differentiation was performed using a cyto-
centrifuge. Slides were centrifuged at 900×g for 5min and
stainedwithDiffQuick-Stain reagent. A differential cell count
was performed by evaluating >300 cells with an optical
microscope [14].
2.7. Lung Histology and Immunohistochemistry. Lungs were
removed and fixed at a constant pressure 20 cmH2O for
1 15 21 28
Procedure
Days
Intratracheal injection of saline/elastase
Intraperitoneal injection of saline/BbCI
Lung mechanics, BAL, and morphometric analysis
Figure 2: Timeline of the experimental protocol. On the first day
of protocol, animals received intratracheal instillation of elastase
or vehicle. Two hours after the intranasal instillation, animals
received an intraperitoneal injection of treatment [BbCI (SALBC
andELABC) or saline (ELA and SAL)]. On the fifteenth day, animals
received the second dose of treatment [BbCI (SALBC and ELABC)
or saline (ELA and SAL)]. On the twenty-first day, animals received
the last dose of BbCI [BbCI (SALBC and ELABC) or saline (ELA
and SAL)]. On the twenty-eighth day the animals were anesthetized
and tracheostomized and the evaluation of the lung mechanics
and the BAL was performed; the lungs were removed to do the
morphometric analysis.
24 hours in 10% formaldehyde. They were then embedded
in paraffin. Sections were processed, and 3–5𝜇m sections
were obtained. They were stained with hematoxylin-eosin to
measure the mean linear intercept (Lm), Picrosirius to detect
collagen fibers, or Weigert’s Resorcin-Fuchsin to stain elastic
fibers. Slides were coded and were evaluated by researchers
blinded to the protocol design.
Immunohistochemistry was performed using the follow-
ing antibodies: anti-Mac-2 (Cedarlene Lab, Ontario, Canada;
1 : 60000), anti-neutrophils (AbDserotec, Kidlington, UK;
1 : 400), anti-MMP-9 (Santa Cruz Biotechnology, Califor-
nia, USA; 1 : 500), anti-MMP-12 (Santa Cruz Biotechnology,
Dallas, USA; 1 : 100), anti-TIMP-1 (LabVision NeoMarkers,
Fremont, USA; 1 : 400), anti-iNOS (LabVision NeoMarkers,
Fremont, USA; 1 : 500), anti-eNOS (LabVision NeoMarkers,
Fremont, USA; 1 : 100), anti-TNF𝛼 (Santa Cruz Biotechnol-
ogy, Dallas, USA; 1 : 900), anti 8-epi-PGF2𝛼 (Oxford Biomed-
ical Research, Oxford, UK; 1 : 10000) and anti-MUC5ac (Lab-
Vision NeoMarkers, Fremont, USA; 1 : 400).
Immunohistochemical staining was performed using the
biotin-streptavidin peroxidase method. An ABC vectastain
kit (Vector Elite PK-6105, Burlingame, USA) was used as a
secondary antibody. DAB (Sigma-Aldrich, USA) was used as
a chromogen. Sections were counterstained withHarris hem-
atoxylin (Merck, Darmstadt, Germany).
2.8. Morphometric Analysis. Using a conventional morpho-
metric method with a 100 points/50 intercepts grid with a
known area (104 𝜇m2 of total area) attached to a microscope
eyepiece. The number of positive cells in the alveolar septum
was determined by the number of positive cells in each field
divided by the number contacting the alveolar septum. The
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number of positive cells in the airway wall was determined
by the number of positive cells in each field divided by the
number contacting the airway wall area. The results were
expressed as cells/area (104 𝜇m2). Volume fraction of 8-iso-
PGF2𝛼 and collagen and elastic fibers in the alveolar septum
or airway walls was determined by dividing the number of
points hitting the positive tissue by the total number of points
hitting alveolar septum or airway walls. The results were
expressed as percentages. A total of 10 fields for the alveolar
septum and 9 fields for the airways per animal were randomly
examined at a magnification of 1000x [15].
2.9. Data Analysis. Statistical analyses were performed using
SigmaStat Software (SPSS Inc., Chicago, IL, USA). Normality
was assessed by using a Kolmogorov-Smirnov test. Data were
evaluated using a One-Way Analysis of Variance. Multiple
comparisons were made using a Holm-Sidakmethod. Values
were expressed as a mean ± standard error (SE). A 𝑝 value <
0.05 was considered significant.
3. Results
3.1. LungMechanics. Figure 3(a) shows the respiratory system
elastance (Ers) values for all the experimental groups. There
was an increase in the ELA group compared to the control
groups (𝑝 < 0.05). The animals that received elastase and
were treated with BbCI had a significant reduction in Ers
compared to the ELA group (𝑝 < 0.05).
Figure 3(b) shows the respiratory system resistance (Rrs)
values for all the animals. The animals that received BbCI
(SALBC and ELABC) had decreased Rrs values compared to
the SAL group (𝑝 < 0.05).
Figure 3(c) shows the airway resistance (Raw) values for
the four experimental groups. The ELA group had increased
Raw values compared to the control groups (𝑝 < 0.05).
The animals treated with the proteinase inhibitor BbCI had
decreased Raw values compared to the ELA group (𝑝 < 0.05)
and had similar values to the controls.
Figure 3(d) shows the lung tissue elastance (Htis) values
for all the experimental groups.TheELA group had increased
Htis compared to the control groups (𝑝 < 0.05). The
animals that received elastase andwere treatedwith BbCI had
similar values to the controls and had a significant attenuation
compared to ELA animals (𝑝 < 0.05).
Figure 3(e) shows the lung tissue damping (Gtis) values
for all the animals. There were no significant differences
between the groups.
3.2. Bronchoalveolar Lavage (BAL). Figure 4(a) shows the
leukocyte counts in the BAL samples from all the experimen-
tal groups. The elastase-induced group had a greater total
number of cells than the control groups (𝑝 < 0.05). In the
ELABC group we observed a decrease in the total number
of leukocytes compared to the elastase-induced group (𝑝 <
0.05).
The macrophage counts in the BAL samples from all
the experimental groups are presented in Figure 4(b). The
elastase-induced groups (ELA and ELABC) had greater
values than the control groups (SAL and SALBC, 𝑝 < 0.05).
There were no differences between the ELA and ELABC
groups.
Figure 4(c) also shows the neutrophil counts from the
BAL samples from all the experimental groups. The elastase-
treated group had greater values than the control groups (𝑝 <
0.05).The animals that received elastase andwere treatedwith
BbCI (ELABC) had decreased neutrophil counts compared
to the ELA group (𝑝 < 0.05). The lymphocyte counts from
the BAL samples from all the experimental groups are also
shown in Figure 4(a). The elastase-induced groups (ELA and
ELABC) had greater values than the control groups (SAL and
SALBC, 𝑝 < 0.05). There were no differences between the
ELA and ELABC groups.
3.3. Morphometric Analysis
3.3.1. Mean Linear Intercept (Lm). Figure 5 shows the Lm
values for all the experimental groups. The elastase-induced
groups (ELA and ELABC) had greater values than the control
groups (𝑝 < 0.05). The animals that received elastase
and were treated with BbCI (ELABC) had decreased Lm
measurements compared to ELA (𝑝 < 0.05).
3.3.2. Lung Inflammation. The inflammatory cells count
present in the alveolar septa is shown in Tables 1 and 2 for
all the experimental groups. In the alveolar septa, we found
an increase in neutrophils, macrophages, and TNF𝛼-positive
cells in the ELA group compared to controls (𝑝 < 0.05). The
treatment with the proteinase inhibitor BbCI, in the animals
that received elastase, attenuated the increase of neutrophils
and macrophages in the alveolar septa compared with the
ELA group (𝑝 < 0.05). There were no differences between
the SAL and SALBC groups.
When we analyzed the airways, we obtained similar
results. There was an increase in neutrophils and TNF𝛼-
positive cells in the airway walls in ELA group comparedwith
the SAL and SALBC groups (𝑝 < 0.05). Treatment with the
proteinase inhibitor BbCI in the ELABC group reduced the
number of neutrophils and TNF𝛼-positive cells in the airway
walls compared with the ELA group (𝑝 < 0.05). There were
no differences between the SAL and SALBC groups.
3.3.3. Extracellular Matrix Remodeling. The analysis of cells
staining positively for extracellular matrix is shown in Table 1
for cells in the alveolar septa and in Table 2 for cells in the
airway walls for all the experimental groups. In the alveolar
septa, there was an increased volume fraction of collagen and
elastic fibers in the ELA group compared with the SAL and
SALBC groups (𝑝 < 0.05). In the ELABC group, there was a
reduction in the volume fraction of collagen and elastic fibers
compared with the ELA group (𝑝 < 0.05). The collagen fiber
values for the ELABC group were higher than those for the
SAL and SALBC groups (𝑝 < 0.05). When we analyzed the
airway wall remodeling, we obtained similar results. There
was an increase in the volume fraction of collagen and elastic
fibers in the ELA group compared with the SAL and SALBC
groups (𝑝 < 0.05). Treatment with the proteinase inhibitor in
the ELABCgroup reduced the volume fraction of the collagen
and elastic fibers compared with the ELA group (𝑝 < 0.05).
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Figure 3: (a) Mean and SE of respiratory system elastance (Ers) of all experimental groups. ELA group was greater than control groups
(∗𝑝 < 0.05), and ELABC had a reduction compared to ELA (#𝑝 < 0.05). (b) Mean and SE of respiratory system resistance (Rrs) in all animals.
Animals that received BbCI (SALBC and ELABC) had a decrease in comparison to SAL (∗𝑝 < 0.05). (c) Mean and SE of airway resistance
(Raw) of four experimental groups. Animals that received elastase (ELA) had greater values than SAL and SALBC groups (∗𝑝 < 0.05). The
treatment with proteinase inhibitor (ELABC) attenuated this increase (#𝑝 < 0.05). (d) Mean and SE of tissue elastance (Htis) of all animals.
Animals that received elastase (ELA) had greater values than SAL and SALBC groups (∗𝑝 < 0.05). The treatment with BbCI (ELABC)
attenuated this increase (#𝑝 < 0.05). (e) Mean and SE of lung tissue damping (Gtis) of all experimental groups. There were no significant
differences among groups.
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Figure 4: (a) Mean and SE of BAL total cells of all experimental groups. The elastase-induced group had a greater total number of cells than
the control groups (∗𝑝 < 0.05). The treatment with BbCI (ELABC) attenuated this increase compared with ELA group (#𝑝 < 0.05). (b) Mean
and SE of the macrophage counts in the BAL of all animals. Animals that received elastase (ELA and ELABC) had greater values than SAL
and SALBC groups (∗𝑝 < 0.05). There were no differences between the ELA and ELABC groups. (c) Mean and SE of neutrophil counts from
the BAL samples of all experimental groups. The elastase-induced group (ELA) had greater values than the control groups (∗𝑝 < 0.05). The
treatment with proteinase inhibitor (ELABC) attenuated this increase (#𝑝 < 0.05). (d) Mean and SE of the lymphocyte counts in the BAL of
all animals. The elastase-induced groups (ELA and ELABC) had greater values than the control groups SAL and SALBC (∗𝑝 < 0.05). There
were no differences between the ELA and ELABC groups.
We observed an increase in the number of MMP-9-,
MMP-12-, and TIMP-1-positive cells in the alveolar septa of
the ELA group compared with the SAL and SALBC groups
(𝑝 < 0.05). In the ELABC group the number of MMP-9-
, MMP-12-, and TIMP-1-positive cells in the alveolar septa
was diminished compared with the ELA group (𝑝 < 0.05).
In the airway walls of the ELABC group, the number of
MMP-9- and MMP-12-positive cells was higher than in the
SAL and SALBC groups (𝑝 < 0.05). The airway wall
analysis revealed increased numbers of MMP-9-, MMP-12-,
and TIMP-1-positive cells in the ELA group compared with
the SAL and SALBC groups (𝑝 < 0.05). In the ELABC
group, the number of MMP-9- and MMP-12-positive cells
was decreased in the airway walls compared with the ELA
group (𝑝 < 0.05). However, there were no differences in the
number of TIMP-1-positive cells between the groups.
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Table 1: Effect of BbCI treatment on positive cells in alveolar septum of all groups. Data are presented as mean ± SE. ELA group had greater
values than control groups (SAL and SALBC) in all alveolar septa parameters. The group that was treated with BbCI inhibitor (ELABC)
had attenuated this response in macrophages, neutrophils, collagen fibers, elastic fibers, MMP-9- and MMP-12-positive cells, and iNOS- and
8-iso-PGF2𝛼-positive cells. ∗𝑝 < 0.05 compared to SAL and SALBC groups. #𝑝 < 0.05 compared to ELA group.
Alveolar septum
Inflammatory response SAL ELA SALBC ELABC
Macrophages (cells/104 𝜇m2) 3.55 ± 0.3 17.50 ± 2.3∗ 5.00 ± 0.3 9.48 ± 1.1∗,#
Neutrophils (cells/104 𝜇m2) 5.87 ± 0.6 20.03 ± 0.7∗ 9.33 ± 0.7 13.01 ± 0.4#
TNF𝛼 (cells/104 𝜇m2) 2.21 ± 0.2 10.41 ± 0.6∗ 2.43 ± 0.3 10.01 ± 0.4∗
Remodelling response SAL ELA SALBC ELABC
Collagen fibers (%) 8.80 ± 0.1 12.12 ± 0.1∗ 8.96 ± 0.1 9.98 ± 0.2∗,#
Elastic fibers (%) 0.32 ± 0.03 0.43 ± 0.03∗ 0.37 ± 0.02 0.34 ± 0.02#
MMP-9-positive cells/104 𝜇m2 8.63 ± 1.2 20.69 ± 1.3∗ 9.89 ± 0.7 11.92 ± 0.1#
MMP-12-positive cells/104 𝜇m2 10.88 ± 1.4 26.17 ± 2.5∗ 11.22 ± 0.5 12.20 ± 0.6#
TIMP-1-positive cells/104 𝜇m2 3.55 ± 0.3 17.50 ± 2.3∗ 5.00 ± 0.3 9.48 ± 1.1#
Oxidative stress response SAL ELA SALBC ELABC
iNOS-positive cells/104 𝜇m2 5.51 ± 0.2 20.55 ± 1.2∗ 6.03 ± 0.5 12.97 ± 1.1∗,#
eNOS-positive cells/104 𝜇m2 3.06 ± 0.2 8.93 ± 0.4∗ 3.58 ± 0.2 8.13 ± 0.4
8-iso-PGF2𝛼-positive cells/104 𝜇m2 6.17 ± 0.6 16.52 ± 0.6∗ 6,74 ± 0.3 11.07 ± 1.1#
Table 2: Effect of BbCI treatment on positive cells in airway walls of all groups. Data are presented as mean ± SE. ELA group had greater
values than control groups (SAL and SALBC) in all airway walls parameters. The group that was treated with BbCI inhibitor (ELABC) had
attenuated this response in neutrophils, TNF𝛼, collagen fibers, elastic fibers, MMP-9- and MMP-12-positive cells, and iNOS-positive cells.
∗𝑝 < 0.05 compared to SAL and SALBC groups. #𝑝 < 0.05 compared to ELA group.
Airway walls
Inflammatory response SAL ELA SALBC ELABC
Neutrophils (cells/104 𝜇m2) 2.77 ± 0.3 11.36 ± 0.8∗ 5.03 ± 0.4 6.23 ± 0.3#
TNF𝛼 (cells/104 𝜇m2) 2.58 ± 0.4 10.62 ± 0.8∗ 2.92 ± 0.3 5.27 ± 0.6#
Remodelling response SAL ELA SALBC ELABC
Collagen fibers (%) 5.55 ± 0.1 8.83 ± 0.1∗ 5.61 ± 0.1 6.02 ± 0.2#
Elastic fibers (%) 0.81 ± 0.1 2.23 ± 0.5∗ 1.08 ± 0.0 1.12 ± 0.4#
MMP-9-positive cells/104 𝜇m2 2.07 ± 0.4 12.82 ± 0.6∗ 4.63 ± 0.8 6.59 ± 0.7∗,#
MMP-12-positive cells/104 𝜇m2 3.14 ± 0.3 13.69 ± 0.9∗ 4.13 ± 0.2 8.50 ± 0.7∗,#
TIMP-1-positive cells/104 𝜇m2 2.96 ± 0.2 8.69 ± 0.8∗ 2.85 ± 0.6 8.08 ± 0.6∗
Oxidative stress response SAL ELA SALBC ELABC
iNOS-positive cells/104 𝜇m2 5.35 ± 0.5 20.42 ± 1.1∗ 6.24 ± 0.7 12.78 ± 1.2∗,#
eNOS-positive cells/104 𝜇m2 3.20 ± 0.2 8.86 ± 0.7∗ 3.80 ± 0.3 7.96 ± 0.4
8-iso-PGF2𝛼-positive cells/104 𝜇m2 5.91 ± 0.8 15.36 ± 1.9∗ 7.65 ± 0.5 15.30 ± 1.2∗
3.3.4. Oxidative Stress. The positively stained oxidative stress
cell counts in the alveolar septa airway walls are shown in
Tables 1 and 2, respectively, for all the experimental groups. In
the alveolar septa, there was an increase in iNOS- and eNOS-
positive cells in the ELA group compared with the SAL and
SALBC groups (𝑝 < 0.05). In the ELABC group, we observed
a reduction in the number of iNOS-positive cells compared
with the ELA group (𝑝 < 0.05). However, the number of
eNOS-positive cells was unchanged. The number of iNOS-
positive cells in the ELABC group increased compared with
the SAL and SALBC groups (𝑝 < 0.05). When we analyzed
the airway walls, we observed similar results. There was an
increase in iNOS- and eNOS-positive cells in the ELA group
compared with the SAL and SALBC groups (𝑝 < 0.05). In
the ELABC group, the number of iNOS-positive cells was
reduced compared with the ELA group (𝑝 < 0.05). There was
an increase in the iNOS-positive cells in the ELABC group
compared with SAL and SALBC groups (𝑝 < 0.05).
The volume fraction of 8-iso-PGF2𝛼 in the alveolar septa
analysis revealed an increase in the ELA groups compared
with the SAL and SALBC groups (𝑝 < 0.05). We found
that the proteinase inhibitor BbCI attenuated this increase
(𝑝 < 0.05) compared with the ELA animals. However, in
the airway walls, the volume fraction of 8-iso-PGF2𝛼 in the
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Figure 5: Mean and SE of Lm values and the representative pho-
tomicrographs, of the four experimental groups. Elastase-induced
groups (ELA and ELABC) had greater values than control groups
(∗𝑝 < 0.05). Animals that received elastase and were treated with
BbCI (ELABC) showed a decrease when compared with elastase-
induced mice (ELA) (#𝑝 < 0.05).
ELA and ELABC groups was increased compared with the
SAL and SALBC groups (𝑝 < 0.05). However, there was no
difference between the ELA and ELABC groups.
3.4. Mucin-Positive Cells. The counts for MUC5ac-positive
cells in the airway walls are shown in Figure 6 for all the
experimental groups.There was an increase in the number of
MUC5ac-positive cells in the airways of the ELA and ELABC
groups compared with the SAL and SALBC groups (𝑝 <
0.05). In the ELABC group we observed a reduction in the
number of MUC5ac-positive cells compared with the ELA
group (𝑝 < 0.05).
3.5. Qualitative Analysis. Representative immunohistochem-
istry photomicrographs of the murine lung alveolar septa of
the four experimental groups are shown in Figure 7. The
sections were stained to identify macrophages ((a), (b), (c),
and (d) panels, ×400) or neutrophils ((e), (f), (g), and (h)
panels, ×400) or to stain for MMP-12 ((i), (j), (k), and (l)
panels, ×400) or iNOS ((m), (n), (o), and (p) panels, ×400).
There was an increase in the number of macrophages, neu-
trophils, andMMP-9- and iNOS-positive cells in the elastase-
treated animals that did not receive the proteinase inhibitor
(ELA group: (b), (f), (j), and (n), respectively) compared with
the saline-treated animals (SAL group: (a), (e), (i), and (m);
SALBC group: (c), (g), (k), and (o)). As shown in Figure 7,
the proteinase inhibitor treatment reduced the number of
macrophages (d), neutrophils (h), andMMP-9- (l) and iNOS-
positive cells (p).
Figure 8 shows representative immunohistochemistry
photomicrographs of the murine airway walls from all the
experimental groups stained for neutrophils ((a), (b), (c), and
(d) panels, ×400) or MMP-9 ((e), (f), (g), and (h) panels,
×400), 8-iso-PGF2𝛼 ((i), (j), (k), and (l) panels, ×400), or
MUC5ac ((m), (n), (o), and (p) panels ×400). The number of
neutrophils and cells positive for MMP-9, 8-iso-PGF2𝛼, and
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Figure 6: Mean and SE of positive MUC5ac cells, in airways of
all experimental groups. Animals that received elastase (ELA) had
greater values than SAL and SALBC groups (∗𝑝 < 0.05). In the
ELABC group we observed a reduction in the number of MUC5ac-
positive cells compared with ELA group (#𝑝 < 0.05).
MUC5ac in the animals treated with elastase was increased
(ELA group: (b), (f), (j), and (n), resp.) compared with the
saline-treated animals (SAL group: (a), (e), (i), and (m);
SALBC group: (c), (g), (k), and (o)). As shown in Figure 8, the
BbCI treatment reduced the number of neutrophils (d) and
cells positive for MMP-9 (h), 8-iso-PGF2𝛼 (l), and MUC5ac
(p).
4. Discussion
In the present study, we tested the hypothesis that the
proteinase inhibitor BbCI from plants ameliorates elastase-
induced pulmonary changes in mice. We showed that BbCI
decreased the elastase-induced lungmechanics abnormalities
and increases in BAL cell counts. It also reduced the inflam-
matory, extracellular matrix remodeling, and oxidative stress
responses in the alveolar septa and airway walls of mice.
The role of proteinases in emphysema is widely accepted.
However, there are uncertainties about which cells and/or
proteinases have key functions in the development and
progression of the disease. Publications variably report that
serine, cysteine, and/ormetalloproteinase classes are themost
likely proteinases involved in COPD pathogenesis [16–18].
Neutrophil elastase, proteinase 3, and cathepsin G are
serine class proteinases stored by polymorphonuclear neu-
trophils (PMN) and monocytes. They are released when
proinflammatory mediators induce PMN and monocyte
degranulation. These serine proteinases have been linked to
lung parenchyma destruction and mucus production [19].
The cysteine class of proteinases includes cathepsin S and L
which are both potent elastases. They promote macrophage-
mediated extracellular matrix protein degradation. The met-
alloproteinase class includes MMP-1, MMP-2, MMP-9, and
MMP-14 and members of the ADAM family of proteinases.
In addition to promoting collagen and elastin degradation,
metalloproteinases also increase MUC5ac expression by air-
way epithelial cells [19, 20].
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Figure 7: Representative photomicrographs of mice lung alveolar septum of four experimental groups submitted to immunohistochemistry:
macrophages (a, b, c, and d panels, ×400), neutrophils (e, f, g, and h panels, ×400), MMP-12 (i, j, k, and l panels, ×400), and iNOS (m, n, o,
and p panels, ×400).
Recently, the development of novel therapeutics targeting
proteinases has been discussed for several diseases. Pro-
teinases are no longer regarded as only extracellular matrix
degrading enzymes. Some proteinases also have important
signaling functions involved in numerous crucial biological
processes. Thus, more selective proteinase inhibitors are
being developed to target these processes [6, 21, 22]. Synthetic
molecules have been developed to assess the therapeutic
efficacy of proteinases in COPD, including CP-471474 [23],
ZD0892 [24], SP-B [25], MR889 [26], and FR901277 [27].
To assess the efficacy of the BbCI treatment on elastase-
induced pulmonary pathologies in mice, we evaluated lung
mechanics 28 days after the elastase instillation. Our results
showed that the BbCI treatment reduced the respiratory elas-
tance (Ers) and resistance (Rrs). The decrease in respiratory
resistance (Rrs) was observed in both groups that received
BbCI (SALBC and ELABC) compared to SAL group. These
results suggest that BbCI might have an airway bronchodila-
tor effect that should be tested in future studies using exper-
imental models of asthma. We have previously shown, using
another proteinase inhibitors, bronchodilator effects of this
class of inhibitor [28, 29].
The BbCI also reduced the tissue resistance elastance
(Htis) and airway resistance (Raw).These results indicate that
intratracheal elastase altered the function of both the airways
and lung parenchyma. In contrast to the results in our study,
previous studies showed that respiratory resistance did not
change in elastase-induced models of emphysema [30, 31].
Some papers report changes in lung mechanics. Using an
elastase-induced model of emphysema, Ito et al. [31] showed
a decrease in respiratory system elastance. The authors
suggest that abnormal collagen remodeling plays a key role
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Figure 8: Representative photomicrographs of mice lung airways walls of all experimental groups submitted to immunohistochemistry:
neutrophils (a, b, c, and d panels, ×400), MMP-9 (e, f, g, and h panels, ×400), 8-iso-PGF2𝛼 (i, j, k, and l panels, ×400), and MUC5ac (m, n,
o, and p panels, ×400).
in pulmonary function and changes inmechanical forces that
occur during the development of emphysema [31]. Using an
elastase-induced animal model, Hantos et al. [30] showed
a decrease in tissue elastance and no alterations in airway
or tissue resistance. In marked contrast to other studies, the
authors of the latter study concluded that tissue destruction
is not linked to pulmonary dysfunction [30]. However, Scuri
et al. [32] showed that elastase treatment leads to increased
production of bradykinin which increases respiratory resis-
tance and elastance.The authors showed that an antagonist of
the bradykinin B2 receptor blocks this response. These data
suggest that the kallikrein-kinin system is involved in this
process [32]. Importantly, although all these studies used an
elastase model, the protocols and doses of elastase delivered
to the animals were significantly different.
In our study, the Lm analysis, which evaluates airspace
enlargement, showed that the proteinase inhibitor BbCI pro-
tects against elastase-induced increases in alveolar size. This
effect may be due to the ability of BbCI to inhibit proteinases
released during elastase-induced inflammation in the distal
lung parenchyma. These results corroborate previous bio-
chemical assays that show that BbCI inhibits both neutrophil
elastase and cathepsin G, both of which have been implicated
in emphysema development [33].
Guarnieri et al. [25] used a high dose elastase-induced
model of emphysema and showed that a peptide-elastase
inhibitor bound to trifluoromethyl prevented enlargement of
the alveoli of mice that received elastase. Suzuki et al. [34]
studied the effects of curcumin in an animalmodel of emphy-
sema and showed that the yellow pigment from turmeric
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reduced the Lm that developed in mice treated with elastase
or chronically exposed to cigarette smoke. Shapiro et al. [3]
studied neutrophil elastase-deficient mice exposed to ciga-
rette smoke and showed that these mice had a 59% reduction
in emphysema development (measured by Lm) compared
with smoke-exposed wild type mice.
The anti-inflammatory effect of BbCI was also observed
in the bronchoalveolar lavage samples in our study. The total
number of BAL leukocytes and neutrophils was decreased
in the animals that received elastase and were treated with
the proteinase inhibitor. These findings could be due to an
inhibition of the neutrophil elastase-mediated recruitment of
inflammatory cells to the lung [3].
We also evaluated the neutrophil, macrophages, and
TNF𝛼-positive cell counts in the lung tissue as well as the
BAL samples. We observed that BbCI decreased the number
of macrophages and neutrophils positive cells in the alveolar
septa and neutrophils and TNF𝛼-positive cells in the airway
walls.
Taken together, these results demonstrate important anti-
inflammatory activity for BbCI in this animalmodel. Oliveira
et al. [35] showed that pretreatment with BbCI effectively
reduces neutrophil migration into the pleural cavity after
carrageenan-induced inflammation.The authors also showed
that BbCI decreased the number of rolling and adherent
leukocytes, as well as leukocyte migrations into the sper-
matic fascia microcirculation after inducing an inflammatory
response [35]. In a model of pulmonary edema caused
by activation of neutrophils, the proteinase inhibitor BbCI
decreased the edema to the samedegree as a substance used as
a reference. The authors concluded that BbCI is a useful tool
for studying the role of neutrophil elastase in pathophysio-
logical processes [12].
We also analyzed the effect of BbCI on elastase-induced
extracellular matrix remodeling by measuring the volume
fraction of collagen and elastic fibers and counting MMP-9-
, MMP-12-, and TIMP-1-positive cells in the alveolar septa
and airway walls. We observed that the BbCI treatment
reduced the volume fraction of elastic and collagen fibers in
alveolar septa and airway walls. Comparing two models of
emphysema in mice, Lopes et al. [36] showed that elastase-
induced mice had higher levels of lung elastin than animals
exposed to smoke for 6months. Collagen type I had the same
pattern in the two groups.The patterns were not significantly
different. However, when they measured lung levels of type
III collagen after 6 months of smoke exposure, these animals
had higher values than the elastase-treated mice [36]. We
observed that the proteinase inhibitor BbCI decreased the
number of MMP-9- and MMP-12-positive cells in both the
alveolar septa and airway walls. Hanaoka et al. [37] studied
the effects of carbocysteine in cigarette smoke-exposed rats.
They reported that MMP-9 expression increased in lung
tissue when animals were exposed to smoke, and a carbocys-
teine treatment reduced this increase [37]. Hautamaki et al.
[38] studied MMP-12 deficient mice chronically exposed to
cigarette smoke and demonstrated that MMP-12 is essential
for the development of cigarette smoke-induced emphysema
[38]. Although high levels ofMMP-9 increased TIMP-1 levels
to restore homeostasis, we did not find that BbCI changed the
TIMP-1 levels in the airways of the elastase-treated lung.
Regarding the oxidative stress response, our data showed
that the proteinase inhibitor BbCI decreased the number of
iNOS-positive cells in both the alveolar septa and airway
walls. It also reduced the volume fraction of 8-iso-PGF2𝛼
in the alveolar septum. BbCI did not reduce the number
of eNOS-positive cells in either site or isoprostane levels in
airways walls. Prado et al. [39] observed that iNOS inhibition
attenuated the airway constriction response in animals with
chronic allergic inflammation [39]. Taken together, iNOS
plays a key role in modulating airway tone and likely explains
the airway resistance alterations in our model.
Because mucus hypersecretion is an important pathology
in COPD and proteinases, including neutrophil elastase [40],
play a key role in this process, we evaluated the number of
MUC5ac-positive cells in the airway walls in our experimen-
tal groups of mice. Our results showed that BbCI reduced
the number of MUC5ac-positive cells in the airways of mice
likely by inhibiting neutrophil elastase.
5. Conclusion
In conclusion, BbCI was shown to be effective in reducing
elastase-induced pulmonary mechanics changes, lung tis-
sue destruction, inflammatory alterations, and extracellular
matrix remodeling and oxidative stress in animals that have
received intratracheal elastase. Nevertheless, further studies
are needed to elucidate the mechanisms by which BbCI
protects the lung. Based on our findings, it may be considered
as a potential therapeutic tool in the COPD management.
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